News|Articles|November 13, 2026

FAQ: XDR Shigella

Here is some important information around this pathogen and the intestinal infection.

Extensively drug-resistant (XDR) Shigella cases continue to rise in Los Angeles County, where the Department of Public Health (LAC DPH) identified 68 cases in 2024, up from 45 in 2023 and 5 in 2021.¹ In June 2025, LAC DPH issued a health advisory warning providers about the increase and the limited antimicrobial options available for treatment.¹ Infections have disproportionately affected men who have sex with men (MSM) and people living with HIV, who accounted for approximately one-third of county XDR cases reported between 2019 and 2024.¹

Related to this article

November 12th, 2026

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups

Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.

November 12th, 2026

CDC Investigators of Enteric Fever Favor Tailored Treatment

Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.

November 11th, 2026

CDC Updates Report on Antimicrobial Resistance

The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.

November 10th, 2026

CDC: NDM Drives 92% Rise in Carbapenemase-Producing CRE Among US Children

A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.

November 10th, 2026

A Portal–Systemic Infectious Cascade: Invasive Amoebiasis Leading to Septic Portal Vein Thrombosis and Endocarditis

Here is a case that was linked to a unique travel history and led to a series of acute health issues.

November 8th, 2026

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

November 8th, 2026

A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.

November 7th, 2026

Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.